Currently, six different CAR T-based therapies are FDA and EMA approved, where two of them target B-cell Maturation Antigen (BCMA), expressed on multiple myeloma cells [6], and four of the approved CAR T-cell products are used to treat CD19+ B cell malignancies [7]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.